Long-term Survival after Aortic Valve Replacement with the Mitroflow Bioprosthesis: a Comparative Study


  • Alexander Manché Cardiothoracic Department Mater Dei Hospital Malta
  • Liberato Camilleri Department of Statistics and Operations Research, Faculty of science, University of Malta




Mitroflow aortic bioprosthesis, premature structural valve degeneration, long-term survival


Background  Recent case reports of early structural degeneration of the Mitroflow valve have cast doubts on the suitability of this bioprosthesis, particularly in the smaller sizes, and in younger patients. We studied long-term patient survival, in a comparative study, as a marker of success after aortic valve replacement.

Methods  Long-term survival in 142 consecutive patients implanted with the Mitroflow valve was compared, using the Kaplan-Meier method, with a control group of 149 patients receiving different bioprostheses. Ninety two percent of patients were over 70 and the Mitroflow was used preferentially in smaller sizes.

Results Long-term survival in patients who received a Mitroflow valve was equivalent to controls. Four documented cases of premature structural valve degeneration (3 Mitroflow, 1 Perimount) required a second intervention.

Conclusions The Mitroflow compared favourably with other valves in our practice. Although a few patients required further treatment this had no significant adverse impact on overall survival.

Author Biographies

Alexander Manché, Cardiothoracic Department Mater Dei Hospital Malta

Chairman Department of Cardiothoracic Surgery

Vice president, Maltese Cardiac Society

Liberato Camilleri, Department of Statistics and Operations Research, Faculty of science, University of Malta

Head of Department of Statistics and Operations Research


National Statistic Office Malta https://www.facebook.com/nsomalta/

Gerosa G, Tarzia V, Rizzoli G, Bottio T. Small aortic annulus: the hydrodynamic performances of 5 commercially available tissue valves. J Thorac Cardiovasc Surg. 2006;131:1058-1064 doi:10.1016/jtcvs.2005.12.034

Sénage T, Le Tourneau T, Foucher Y, Pattier S, Cueff C, Michel M, et al. Early structural valve degeneration of Mitroflow aortic bioprosthesis: Mode, incidence and impact on outcome in a large cohort of patients. Circulation 2014;CIRCULATIONAHA.114.010400

Joshi V, Prosser K, Richens D. Early prosthetic valve degeneration with Mitroflow aortic valves: determination of incidence and risk factors. Interact Cardiovasc Thorac Surg 201419;36-40 doi:10.1093/icvts/ivt372.275

Blasco-Lucas A, Rabasa JM, Ortiz D, Miralles A. Early structural valve deterioration of the Mitroflow aortic bioprosthesis: Will the new anticalcification treatment change anything?

Rev Esp Cardiol. 2017;70:1152 doi: 10.1016/j.rec.2017.08.008

Le Tourneau T, Savoye C, McFadden EP, Grandmougin D, Carton HT, Hennequin JL, Dubar A, Favad G, Warembourg H. Mid-term comparative follow-up after aortic valve replacement with Carpentier-Edwards and Pericarbon pericardial protheses. Circulation. 1999;100(19 suppl):II 11-II 16 doi:10.1161/01.cir.100.2uppl_2.ii-11

Diaz R, Hernandez-Vaquero D, Silva J, Pascual I, de la Hera JM, Leon V, Martin M, Barriales V, Colunga S, del Valle R, Moris C. Real structural valve deterioration of the Mitroflow aortic bioprosthesis: Competing risk analysis. Rev Esp Cardiol. 2017;70:1074-1081 doi: 10.1016/j.rec.2017.02.041

Piccardo A, Blossier JD, Le Guyader A, Orsel I, Sekkal S, Cornu E, Laskar M. Fate of Mitroflow aortic bioprosthesis: An 18-year experience

J Thorac Cardiovasc Surg. 2015;151(3) doi: 10.1016/jtcvs.2015.10.020

Mosquera VX, Bouzas-Mosquera A, Velasco-Garcia C, Muniz J, Estévez-Cid F, Portela-Torron F, Herrera-Norena JM, Cuenca-Castillo JJ. Long-term outcomes and durability of the Mitroflow aortic bioprosthesis. J Card Surg. 2016;31:264-273 doi:10.1111/jocs.12726. Epub 2016 Mar 14

Ruvolo G, Pisano C, Balistreri CR, Maresi E, Triolo OF, Argano V, Bassano C, Vacirca SR, Nardi P, Orlandi A. Early structural degeneration of Mitroflow aortic valve: another issue in addition to the mismatch? J Thorac Dis 2018 doi:10.21037/jtd.2018.03.137

Fleisher AG, LaFaro RJ, Moggio RA. Immediate structural valve deterioration of the 27-mm Carpentier-Edwards aortic pericardial bioprosthesis. Ann thorac Surg 2004;77:1443-1445 doi:10.1016/s0003-4975(03)01253-0

Minami K, Zittermann A, Schulte-Eistrup S, Koertke H, Körfer R. Mitroflow synergy prostheses for aortic valve replacement: 19 years experience with 1,516 patients. Ann Thorac Surg. 2005;80:1699-1705 doi:10.1016/j.athoracsur.2005.04.053

Yankah CA, Schubel J, Buz S, Siniawski H, Hetzer R. Seventeen-year clinical results of 1,037 Mitroflow pericardial heart valve prostheses in the aortic position. J Heart Valve Dis. 2005;14:172-179.

Webb J, Parkin D, Tendel K, Simitsis P, Roxburgh J, Chambers JB. A comparison of early redo surgery rates in Mosaic porcine and Perimount bovine pericardial valves. Eur J Cardiothorac Surg. 2018 Mar 20. doi:10.1093/ejcys/ezy113

Philip R, Kumar TK, Waller BR, McCoy M, Knott-Craig CJ. Near catastrophic accelerated structural degeneration of the Perimount Magna pericardial bioprosthesis in children. Ann thorac Surg 2016;102:308-311 doi:10.1016/j.athoracsur.2015.09.088

Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. Heart. 2006;92:1022-1029 doi:10.1136/hrt.2005.067363

Rodriguez-Gabella, Voisine P, Dagenais F, Mohammadi S, Perron J, Dumont E, Puri R, Asmarats L, Coté M, Bergeron S, Pibarot P, Rodés-Cabau J. Long-term outcomes following surgical aortic bioprosthesis implantation. J Am Coll Cardiol 2018(71) doi: 10.1016/jacc.2018.01.059

Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy V. Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50-69 years. Eur Heart J. 2016;37:2658-2667 doi:10.1093/eurheart/ehv580

Manché A, Camilleri L, Gauci D. Does aortic valve replacement restore normal life expectancy? A twenty-year relative survival study. Int Cardiovasc Forum J 2016(6) doi: 10.17987/icfj.v610.138

Manche A, Casha A, Camilleri L. Long-term survival following aortic valve replacement: the influence of age, prosthesis-patient mismatch and indexed effective orifice area. Int Cardiovasc Forum J 2017(11) doi:10.17987/icfj.v11i0.432

Banbury MK, Cosgrove DM, White JA, Okies JA. Age and valve size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg. 2001;72:753-757 doi:10.1016/S0003-4975(01)02992-7

Weerasinghe A, Edwards M-B, Taylor KM. First redo heart valve replacment. A 10-year analysis. Circulation 1999;99:655-658 doi:10.1161/01.CIR.99.5.655

Von Knobelsdorff F, Dieringer MA, Greiser A, Schulz-Menger J. In vitro assessment of heart valve bioprostheses by cardiovascular magnetic resonance: Four-dimensional mapping of flow patterns and orifice planimetry. Eur J Cardiothorac Surg 2011;40:736-742 doi:10.1016/j.ejcts.2010.12.040

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journal. International Cardiovascular Forum Journal 2015;2:2 doi:10.17987/icfj.v2i1.4






Original Article